Product category:
Laboratory and scientific consultancy services
News Release from: Bioimage
Edited by the Laboratorytalk Editorial
Team on 25 January 2002
Danish life sciences company boosted
BioImage, an emerging drug discovery company spun out of Novo Nordisk, has announced the closing of a euro 15.2 million (US$13.6 million) second round financing package
Abingworth Management and Funds advised by Apax Partners, an existing shareholder, led the new financing round and were joined by a further new investor the Danish based company Novo The capital raised will be used for exploiting the company's unique technologies in cell based screening and the continued drug discovery effort focused on identifying more selective drug candidates within a number of therapeutic areas
This article was originally published on Laboratorytalk on 24 Feb 2003 at 8.00am (UK)
Related stories
First spinal study of bone substitute
Study will measure performance of synthetic bone graft substitute in 30 patients undergoing spinal fusion for degenerative disc disease
Acquisition creates global CRO
Advanced Clinical Sciences becomes a global player in clinical research with the takeover of a Swiss CRO called CRC
Newly appointed Patrik Dahlén, CEO of BioImage, said: "BioImage has an enormous scientific and commercial opportunity to create new drug candidates through our ability to monitor intracellular events and protein translocation in real time.
Redistribution, the visualisation and measurement of protein translocation in living cells, was merely a scientific concept a couple of years ago, but is now widely recognised in the industry.
Using this novel technology we have already generated early drug candidates with a new mode of action.
Further reading
Achema 2003 - world forum for process industries
27th International exhibition and congress on chemical engineering, environmental protection, and biotechnology
Achema rises to market challenge
Despite the economic uncertainty of the time, the mammoth process industries event in Frankfurt this May will be almost as big as the last record-breaking event, in 2000
We are delighted to have the support of high quality life science investors in this financing round.
Their experience and contacts within the global life science area as well as local coverage will be extremely valuable as we build our company." David Leathers, director at Abingworth Management, said: "BioImage is our first investment in Denmark.
We pursue investment opportunities where we find breakthrough science with clear commercial opportunities, which BioImage has already shown through its partnership with Amersham Biosciences.
" Stephen Thompson, director of Apax Partners, said: "Apax Partners facilitated BioImage's spin off from Novo Nordisk in 1999.
We invested in a company with a proven scientific track record and an excellent portfolio of patent applications.
We are delighted to participate in this subsequent financing round, investing in a company that has a commercial, viable patent portfolio and an enormous potential as a result of its strong management team, its novel drug discovery approach and pipeline of projects.
" Ulrik Spork, chief investment officer at Novo, said: "We have been following BioImage's achievements for some years.
It is a prime example of commercialisation of unique Danish research, and we are thrilled to be an investor in the company".
BioImage uses its expertise in Redistribution technologies to discover drug candidates that change the activity of specific signaling pathways without inhibiting the catalytic activity of signaling proteins.
The company was spun off from Novo Nordisk in 1999 with venture funds advised by Apax Partners.
Today, the company employs approximately 40 people at its research facility in Copenhagen.
• Bioimage: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
